Keryx Biopharmaceuticals (KERX) : During the past 4 weeks, traders have been relatively bearish on Keryx Biopharmaceuticals (KERX), hence the stock is down -7.45% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -9.65% relative to the S&P 500. The 4-week change in the price of the stock is -7.57% and the stock has fallen -9.19% in the past 1 week.
The stock has recorded a 20-day Moving Average of 5.39% and the 50-Day Moving Average is 27.68%.The 200 Day SMA reached 17.7%. Keryx Biopharmaceuticals Inc. has dropped 36.15% during the last 3-month period . Year-to-Date the stock performance stands at -17.82%.
Keryx Biopharmaceuticals (NASDAQ:KERX): After opening at $4.15, the stock dipped to an intraday low of $4.04 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $4.171 and the buying power remained strong till the end. The stock closed at $4.15 for the day, a gain of 0.48% for the day session. The total traded volume was 1,806,089. The stocks close on the previous trading day was $4.13.
Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases. Its lead product Auryxia (ferric citrate), an oral, absorbable iron-based compound, received marketing approval from the United States Food and Drug Administration (FDA), for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. The approval of Auryxia was based on data from its Phase III registration program, in which Auryxia effectively reduced serum phosphorus levels to well within the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines range of 3.5 to 5.5 mg/dL. In addition to the effects on serum phosphorus levels, Auryxias pharmacodynamic properties resulted in increased ferritin, iron and transferrin saturation (TSAT).